<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To assess the efficacy of <z:chebi fb="0" ids="3962">curcumin</z:chebi> in delaying development of type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (T2DM) in the <z:e sem="disease" ids="C0362046" disease_type="Disease or Syndrome" abbrv="">prediabetic</z:e> population </plain></SENT>
<SENT sid="1" pm="."><plain>RESEARCH DESIGN AND METHODS: This randomized, double-blinded, placebo- controlled trial included subjects (n = 240) with criteria of <z:e sem="disease" ids="C0362046" disease_type="Disease or Syndrome" abbrv="">prediabetes</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> subjects were randomly assigned to receive either <z:chebi fb="0" ids="3962">curcumin</z:chebi> or placebo capsules for 9 months </plain></SENT>
<SENT sid="3" pm="."><plain>To assess the T2DM progression after <z:chebi fb="0" ids="3962">curcumin</z:chebi> treatments and to determine the number of subjects progressing to T2DM, changes in β-cell functions (homeostasis model assessment [HOMA]-β, C-<z:chebi fb="7" ids="16670">peptide</z:chebi>, and proinsulin/insulin), <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> (HOMA-IR), anti-inflammatory cytokine (adiponectin), and other parameters were monitored at the baseline and at 3-, 6-, and 9-month visits during the course of intervention </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: After 9 months of treatment, 16.4% of subjects in the placebo group were diagnosed with T2DM, whereas none were diagnosed with T2DM in the <z:chebi fb="0" ids="3962">curcumin</z:chebi>-treated group </plain></SENT>
<SENT sid="5" pm="."><plain>In addition, the <z:chebi fb="0" ids="3962">curcumin</z:chebi>-treated group showed a better overall function of β-cells, with higher HOMA-β (61.58 vs. 48.72; P &lt; 0.01) and lower C-<z:chebi fb="7" ids="16670">peptide</z:chebi> (1.7 vs. 2.17; P &lt; 0.05) </plain></SENT>
<SENT sid="6" pm="."><plain>The <z:chebi fb="0" ids="3962">curcumin</z:chebi>-treated group showed a lower level of HOMA-IR (3.22 vs. 4.04; P &lt; 0.001) and higher adiponectin (22.46 vs. 18.45; P &lt; 0.05) when compared with the placebo group </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: A 9-month <z:chebi fb="0" ids="3962">curcumin</z:chebi> intervention in a <z:e sem="disease" ids="C0362046" disease_type="Disease or Syndrome" abbrv="">prediabetic</z:e> population significantly lowered the number of <z:e sem="disease" ids="C0362046" disease_type="Disease or Syndrome" abbrv="">prediabetic</z:e> individuals who eventually developed T2DM </plain></SENT>
<SENT sid="8" pm="."><plain>In addition, the <z:chebi fb="0" ids="3962">curcumin</z:chebi> treatment appeared to improve overall function of β-cells, with very minor adverse effects </plain></SENT>
<SENT sid="9" pm="."><plain>Therefore, this study demonstrated that the <z:chebi fb="0" ids="3962">curcumin</z:chebi> intervention in a <z:e sem="disease" ids="C0362046" disease_type="Disease or Syndrome" abbrv="">prediabetic</z:e> population may be beneficial </plain></SENT>
</text></document>